UBS Raises TSMC Price Target to T$3,400 on Strong AI Chip Demand Outlook 
China Eastern Orders 25 Airbus A330neo Jets in $9.35 Billion Deal to Boost International Expansion 
OpenAI IPO Delay Weighs on SoftBank Shares as AI Valuation Concerns Grow 
Italy Investigates Microsoft Over Microsoft 365 AI Subscription Price Hike 
Johns Hopkins University Lays Off 110 Employees as Federal Research Funding Declines 
Kioxia Targets U.S. Listing as AI Chip Boom Accelerates 
Fortescue Faces Class Action Over Sexual Harassment Claims at Australian Mining Sites 
Nomura Stock Upgraded to Buy by BofA as Stronger ROE and Earnings Growth Boost Outlook 
Trip.com Shares Tumble After Q1 Profit Drops and Weak Revenue Growth Outlook 
Lenovo Shares Slide as AI-Driven Memory Demand Signals Higher DRAM and NAND Prices 
Doncasters Raises $919 Million in NYSE IPO as Aerospace Growth Accelerates 
SpaceX, Charter Communications Explore Mobile Partnership to Expand Starlink Wireless Service 
Bayer Wins Major U.S. Supreme Court Roundup Lawsuit, Shares Surge 
Samsung and SK Hynix Shares Jump After Micron Earnings Boost AI Chip Optimism 
Firmus Partners With Nvidia to Deliver 170,000 AI GPUs in $30 Billion Cloud Infrastructure Deal 
Momenta Launches Hong Kong IPO to Raise Up to $751 Million for AI and Robotaxi Expansion 
Kakaku.com Shares Rise as Bain Capital and LY Corp Prepare Higher Takeover Bid Than EQT 
CAMBRIDGE, Mass. and CROMWELL, Conn., May 04, 2017 -- Cellaria, LLC, a scientific innovator that develops revolutionary new patient-specific models for challenging diseases, and Biological Industries USA (BI-USA), a subsidiary of Biological Industries (Israel), today announced a new sales and marketing agreement to promote custom stem cell services. The partnership combines BI-USA’s strength in stem cell culture media and manufacturing with Cellaria’s comprehensive Stem Cell Services program, which includes industry leading RNA reprogramming and custom differentiation services. Together, the companies will offer one of the industry’s most innovative and comprehensive stem cell service offerings available to biotechnology companies and academic institutions.
|
|||||
As part of the agreement, Cellaria will distribute BI-USA’s stem cell media offering, including its NutriStem® hPSC Medium, a cGMP xeno-free media specifically designed for human pluripotent stem cell culture. Cellaria will also incorporate the product into its stem cell services. BI-USA will market Cellaria's customized stem cell services, establishing an integrated, single source solution for iPS cell line derivation, culture maintenance, banking, characterization and differentiation services.
“BI is one of the most respected names in life sciences today,” said David Deems, chief executive officer at Cellaria. “The company’s strong market presence and innovative media products will enhance our stem cell and RNA reprogramming service offerings and significantly increase the availability and appeal of our combined offerings.”
“This is an important partnership for us,” added Tanya Potcova, chief executive officer of BI-USA. “In combination, our teams bring a wealth of stem cell experience but also share a common goal of creating higher quality, more consistent research outcomes for researchers in the life sciences field. We are pleased to be working with the team at Cellaria to put the best possible tools and support in the hands of our present and future customers.”
Please visit Cellaria and BI at the International Society of Stem Cell Research Annual Meeting in Boston, MA June 14-17, 2017 at booth# 407.
About Cellaria
Cellaria creates high quality, next generation in vitro disease models that reflect the unique nature of a patient’s biology. All models begin with tissue from a patient, capturing clinically relevant details that inform model characterization. For cancer, Cellaria’s cell models exhibit molecular and phenotypic characteristics that are highly concordant to the patient. For RNA-mediated iPS cell line derivation and stem cell services, Cellaria’s cell models enable interrogation of patient and disease-specific mechanisms of action. Cellaria’s innovative products and services help lead the research community to more personalized therapeutics, revolutionizing and accelerating the search for a cure. For more information, visit www.cellariabio.com.
About Biological Industries
Biological Industries (BI) is one of the world’s leading and trusted suppliers to the life sciences industry, with over 35 years’ experience in cell culture media development and cGMP manufacturing. BI’s products range from classical cell culture media to supplements and reagents for stem cell research and potential cell therapy applications, to serum-free, xeno-free media. BI is committed to a Culture of Excellence through advanced manufacturing and quality-control systems, regulatory expertise, in-depth market knowledge, and extensive technical customer-support, training, and R&D capabilities.
Biological Industries USA (BI-USA) is the US commercialization arm of BI, with facilities in Cromwell, Connecticut. Members of the BI-USA team share a history and expertise of innovation and success in the development of leading-edge technologies in stem cell research, cellular reprogramming, and regenerative medicine. For more information, visit www.bioind.com or connect on LinkedIn, Twitter, and Facebook.
Contact: for Cellaria Tim Walsh Walsh Group Marketing 617.512.1641 [email protected] for BI-USA Bill Douglass Gotham Communications, LLC 646-504-0890 [email protected]
